Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Liabilities and Shareholders Equity: 2021-2024

Historic Liabilities and Shareholders Equity for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $1.1 billion.

  • Krystal Biotech's Liabilities and Shareholders Equity rose 26.24% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 billion, marking a year-over-year increase of 26.24%. This contributed to the annual value of $1.1 billion for FY2024, which is 29.02% up from last year.
  • Krystal Biotech's Liabilities and Shareholders Equity amounted to $1.1 billion in FY2024, which was up 29.02% from $818.4 million recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Liabilities and Shareholders Equity registered a high of $1.1 billion during FY2024, and its lowest value of $558.5 million during FY2022.
  • Over the past 3 years, Krystal Biotech's median Liabilities and Shareholders Equity value was $818.4 million (recorded in 2023), while the average stood at $810.9 million.
  • Per our database at Business Quant, Krystal Biotech's Liabilities and Shareholders Equity declined by 10.83% in 2022 and then spiked by 46.54% in 2023.
  • Yearly analysis of 4 years shows Krystal Biotech's Liabilities and Shareholders Equity stood at $626.3 million in 2021, then decreased by 10.83% to $558.5 million in 2022, then soared by 46.54% to $818.4 million in 2023, then grew by 29.02% to $1.1 billion in 2024.